secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-007081
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea ends 2025 with $301.8M cash; Phase 3 HCV data due mid-2026; HEV program advancing
--------------------------------------------------------------------------------

- Cash and investments $301.8M at Dec 31, 2025; cash runway expected through 2027.
- Phase 3 HCV C-BEYOND topline results mid-2026; C-FORWARD results year-end 2026.
- HEV Phase 1 study for AT-587 planned mid-2026; preclinical shows potent nanomolar anti-HEV activity.
- Market survey of 153 top DAA prescribers supports need for new HCV regimen; global HCV market ~$3B net sales annually.
- Atea will evaluate strategic transactions and global commercialization options to maximize reach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312526007081/0001193125-26-007081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312526007081/d800383d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-007081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer